February 25, 2025 03:46 PM EST

Compounders sue FDA over removal of semaglutide from official shortage list

Max Bayer

Pharma Reporter

Drug compounders have sued the FDA to put the weight loss and diabetes drug semaglutide back on an official shortage list, fighting a regulatory decision …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Compounders sue FDA over removal of semaglutide from official shortage list

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

J&J seeks to stop Samsung Bioepis from licensing Stelara biosimilar

Where the money is: The top 100 venture investors in biotech

Lilly pays $10M upfront for Organovo’s FXR agonist program

Hims eyes growth in its weight loss business, despite end of semaglutide shortage

Candel's viral therapy shows promising survival in small pancreatic cancer study

How AI can address ongoing challenges in the life sciences industry

Com­pounders sue FDA over re­moval of semaglu­tide from of­fi­cial short­age list

Pharma Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Compounders sue FDA over removal of semaglutide from official shortage list